Evidence map›Paper›PMID 33721567›Full record

ArticleThe Lancet. Global health2021

Cost-effectiveness of universal HIV testing and treatment: where next?

Jean B Nachega, Ethan D Borre, David W Dowdy, Pascalina Chanda-Kapata, Susan Cleary, Elvin H Geng

Abstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in The Lancet. Global health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Jean B NachegaInfectious Diseases and Microbiology, University of Pittsburgh, Pittsburgh, PA, USA; Center for Global Health, University of Pittsburgh, Pittsburgh, PA, USA; Department of Medicine and Centre for Infectious Diseases, Stellenbosch University Faculty of Medicine and Health Sciences, Cape Town 7505, South Africa; Department of Epidemiology and Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. Electronic address: jbn16@pitt.edu.
Ethan D BorreDepartment of Medicine, Duke University School of Medicine, Durham, NC, USA.
David W DowdyDepartment of Epidemiology and Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Pascalina Chanda-KapataMinistry of Health, Lusaka, Zambia.
Susan ClearyHealth Economics Unit, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.
Elvin H GengDivision of Infectious Diseases, Department of Medicine, Washington University, St Louis, MO, USA; Center for Dissemination and Implementation, Institute for Public Health, Washington University, St Louis, MO, USA.

Funding

African Association for Health Professions Education and ResearchR25TW011217 · FIC · INFECTIOUS DISEASES INSTITUTE · PI ADEJUMO, PRISCA, NACHEGA, JEAN BISIMWA · 2018 to 2023
$3.9M
University of Pittsburgh HIV-Comorbidities Research Training Program in South AfricaD43TW010937 · FIC · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI NACHEGA, JEAN BISIMWA, SEEDAT, SORAYA · 2019 to 2023
$1.2M
Cardiometabolic Outcomes, Mechanisms and approach to prevention of Dolutegravir Associated Weight Gain In South AfricaR21TW011706 · FIC · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KENGNE, ANDRE PASCAL, NACHEGA, JEAN BISIMWA · 2020 to 2021
$345k
FIC NIH HHS D43 TW010937FIC NIH HHS R21 TW011706FIC NIH HHS R25 TW011217
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Anti-HIV AgentsHIV TestingCost-Benefit AnalysisHumansSouth AfricaZambiaAnti-HIV Agents

Identifiers

PMID33721567
PMCPMC8295732

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.